SRR4195671
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.520
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.440
- MYC_TARGETS_V2+0.310
- MITOTIC_SPINDLE+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.180
- MTORC1_SIGNALING+0.150
- SPERMATOGENESIS+0.080
- HYPOXIA+0.050
- ANDROGEN_RESPONSE+0.040
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- COAGULATION-0.390
- INFLAMMATORY_RESPONSE-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- COMPLEMENT-0.370
- XENOBIOTIC_METABOLISM-0.370
- IL2_STAT5_SIGNALING-0.360
- BILE_ACID_METABOLISM-0.350
- IL6_JAK_STAT3_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.919 |
| 2 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.914 |
| 3 | TCGA-91-6847-01A-11R-1949-07 | — | cohortMD1 | 0.906 |
| 4 | SRR650141 | — | — | 0.904 |
| 5 | MDT-AP-0138 | Med | Medulloblastoma | 0.899 |
| 6 | BS_BVSW4GTG | medulloblastoma | — | 0.896 |
| 7 | MDT-AP-3254 | Med | Medulloblastoma | 0.892 |
| 8 | C3L-04013 | — | cohortMD1 | 0.892 |
| 9 | TCGA-33-4587-01A-11R-2125-07 | — | cohortMD1 | 0.890 |
| 10 | BS_N6N147BY | Embryonal tumors | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |